NCT02937012.

Trial name or title	Efficacy and Security of Bezafibrate in Patients with Primary Biliary Cirrhosis without Biochemical Response to Ursodeoxycholic Acid: a Randomized, Double‐blind, Placebo‐controlled Trial
Methods	Randomised, double‐blind, placebo‐controlled clinical trial.
Participants	People with primary biliary cholangitis (non‐responders).
Interventions	Group 1: UDCA + bezafibrate. Further details: bezafibrate 200 mg capsule every 12 hours + UDCA 13 mg/kg/day to 15 mg/kg/day for 12 months. Group 2: UDCA + placebo. Further details: placebo capsule (for bezafibrate 200 mg capsule) every 12 hours + UDCA 13 mg/kg/day to 15 mg/kg/day for 12 months.
Outcomes	Quality of life.
Starting date	October 2016.
Contact information	ericlopezmendez@yahoo.com.mx sergio_sg@hotmail.com
Notes	Status: recruiting.